New class of cholesterol drug proves safe and effective for patients with dyslipidemia
Treatment with PCSK9 antibodies reduces mortality and produces profound reductions in LDL-cholesterol and lipoprotein in patients with dyslipidemia. The results of this systematic review and meta-analysis are being published ...
Apr 27, 2015
0
6